Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING: University hospital. PARTICIPANTS: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. INTERVENTION: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. RESULTS: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). LIMITATION: Single-center study. CONCLUSION: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. PRIMARY FUNDING SOURCE: Burroughs Wellcome Fund and American Diabetes Association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefi cial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been seen with pioglitazone (200,201).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“weight gain was also significantly higher in the treatment group [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“a randomized controlled trial including 101 patients with either pre‐ or type 2 diabetes found that 51% in the Pioglitazone group (45 mg/day) had resolution of NASH and 58% achieved the primary outcome of the study (reduction of ≥2 NAS points in two histologic categories without worsening of fibrosis), both significantly [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“Pioglitazone treatment was also associated with a significant improvement in fibrosis score.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“5) mg/dL 149 (36) 153 (34) 1 (−18 to 19) LDL cholesterol level 0.”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 3×
“Additional secondary outcomes included the following: 1) fasting plasma glucose, fasting plasma insulin, FFA, hemoglobin A1c, fasting plasma lipid profile, adiponectin, and cytokeratin-18 concentrations; 2) total body fat percentage, measured by DXA; 3) hepatic triglyceride content, measured by magnetic resonance and…”
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“001 Fibrosis ≥1-point improvement, n (%) 13 (25) 20 (39) 14 (−6 to 34) 0.”
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Research works printed but not linked: 1
- Bril F, 2015, Diabetes, 64, A337
Cited by
Items 801–900 of 1,001
Tran, Q. T., Bui, T. T., Ngo, L. T., Yang, B. R., Baek, I., Nguyen, V. H., Lee, K. A., Yun, H., Chae, J., Lee, S., et al. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70034 · Cited by 3
PPARidgm shifts in the treatment of metabolic dysfunction–associated steatotic liver disease
Abushamat, L. A., & Barb, D. (2025) · Hepatology · doi:10.1097/hep.0000000000001511 · Cited by 2
Zhang, F., Wang, Z., Zhang, H., & Zuo, Y.-Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696652 · Cited by 3
Li, L., Lui, D. T. W., Fong, C. H.-Y., Chow, W., Au, I. C. H., Xiong, X., Lang, B. H., Wong, C. K. H., & Lee, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02973-5 · Cited by 3
Wood, E. M., Akande, R. O., Iqbal, I., & Albert, S. G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70314 · Cited by 2
Ezz-Eldin, Y. M., Azouz, A. A., Khalaf, M. M., & Ewees, M. G. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2638333 · Cited by 2
Advances in the Pharmacologic Management of MASLD
Madhankumar, S., & Asma, A. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17010017 · Cited by 2
“Randomized controlled trials, including the PIVENS study and subsequent studies in patients with prediabetes or type 2 diabetes, reported improvements in steatosis, inflammation, and ballooning, with increased rates of steatohepatitis resolution [63,64].”
Vettor, R., Petroni, M. L., Dotan, I., Lalazar, G., Haluzík, M., Spearman, C. W., Dave, J. A., Abaalkhail, F. A., Abusnana, S., Alshehri, A. A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10027-8 · Cited by 6
Wei, S., He, Y., Luo, C., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924392 · Cited by 4
Antidiabetic Treatments for Diabetes with Liver Cirrhosis
Sumida, Y. (2020) · Interventions in Obesity & Diabetes · doi:10.31031/iod.2020.03.000566 · Cited by 2
D’Souza, S. M., Yoo Byung, S., Houston, K. V., Patel, A., Parekh, P. J., & Johnson, D. A. (2021) · Annals of Clinical Gastroenterology and Hepatology · doi:10.29328/journal.acgh.1001030 · Cited by 2
Albhaisi, S. A. M., & Sanyal, A. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00121-3 · Cited by 2
Anand, A. C., & Acharya, S. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.01.008 · Cited by 3
Pokoly, B., & Somogyi, A. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32783 · Cited by 3
Imawari, M., Nagase, M., Torshin, I. Y., & Громова, О. А. (2023) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2023.206 · Cited by 3
Mohamed, M. A.-E., Rihan, S., Elbakry, M. M. M., & Moselhy, S. S. (2024) · Natural Product Research · doi:10.1080/14786419.2024.2316328 · Cited by 2
“Even though a recent 18-month trial found that pioglitazone medication along with a hypocaloric diet (500 kcal/day) improved the liver histology in 51% (26/50) of individuals with NASH and diabetes, its effectiveness needs to be assessed in larger patient cohorts (Cusi et al. 2016).”
Clinical management of MASLD and MASH—An overview
Horn, P., & Newsome, P. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00019-4 · Cited by 2
Leite, A. R., Dias, J., Godinho, T., Correia-Chaves, J., Borges‐Canha, M., Lourenço, I. M., Leite-Moreira, A. F., & Neves, J. S. (2024) · Endocrinology Insights · doi:10.1159/000541442 · Cited by 5
Youssif, M., Eid, R. A., Rabea, H., Madney, Y. M., Khaled, A., Orayj, K. M., Attia, D. I., & Wahsh, E. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091279 · Cited by 2
“Pioglitazone has demonstrated histological benefits in MASLD, but may be associated with weight gain and fluid retention [31].”
Vilar‐Gómez, E., & Adams, L. A. (2016) · Annals of Internal Medicine · doi:10.7326/m16-1303 · Cited by 2
“Patients were randomly assigned to daily pioglitazone (initially 30 mg, later titrated to 45 mg) or placebo over 18 months, along with dietary counseling (8).”
MethodPalmieri, B., Corazzari, V., BRASILE, D. G. P., Sangiovanni, V., & VADALÀ, M. (2021) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.20.02738-5 · Cited by 3
Association of insulin resistance and non-alcoholic fatty liver disease
Mishina, E. Е., Mayorov, A. Y., Bogomolov, P., Liusina, E. O., & Bueverov, A. O. (2021) · Diabetes Mellitus · doi:10.14341/dm12234 · Cited by 2
Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
Lee, S. J., & Lee, B. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.1.38 · Cited by 2
Koutoukidis, D. A., Morris, E. M., Henry, J. A., Shammoon, Y., Zimmerman, M., Michalopoulou, M., Jebb, S. A., & Aveyard, P. N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250385 · Cited by 2
“Firstly, many large-scale trials calculated their sample size based on a retention of 85–90%, but on average did not achieve this [11, 12, 39, 42, 47].”
BackgroundDavidson, M. B. (2020) · Cited by 2
Blinding in Clinical Trials for Chronic Liver Diseases
Ortiz, V., Ellenberg, S. S., & Weinberg, E. M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723753 · Cited by 2
Bril, F. (2021) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2021.06 · Cited by 2
Self-citationAdvances in Pharmacotherapeutics, Metabolic Surgery, and Technology for Diabetes
Guerron, A. D., Davis, G. M., & Pasquel, F. J. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.009 · Cited by 2
Lee, C. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.01.005 · Cited by 3
Advances in metformin for the treatment of non-alcoholic fatty liver disease in children
Wu, Q., Zeng, S., Peng, J., Yuan, Y., Zhu, Z., Xie, Z., Huang, Z., Huang, J.-S., Lai, J., Chen, J.-A., et al. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2118112 · Cited by 2
Petunina, N. A., Валерьевна, Г. Е., Кузина, И. А., Недосугова, Л. В., Степановна, М. Н., & Эдуардовна, Т. М. (2022) · Diabetes Mellitus · doi:10.14341/dm12859 · Cited by 3
Lipid-Induced Insulin Resistance
Mukhopadhyay, S., Dutta, D., & Ganguly, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812019-4.00014-3 · Cited by 2
YADAV, Y. R., Syn, W., & Basu, R. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0158 · Cited by 2
“These are clinically relevant because cumulative studies suggest that the presence of NAFLD/NASH may independently increase the risk of cardiovascular events, and may also increase the risk of incident T2DM and worsen glycemic control.(5,6)”
BackgroundAcupuncture for type 2 diabetes mellitus with nonalcoholic fatty liver disease
Li, M., Yao, L., Huang, H., Wang, G., Yu, B., Zheng, H., & Wang, H. (2021) · Medicine · doi:10.1097/md.0000000000026043 · Cited by 2
Rotman, Y., & Sanyal, A. J. (2017) · Gut · doi:10.1136/gutjnl-2017-314263 · Cited by 2
Yuan, L., McCommis, K. S., & Neuschwander‐Tetri, B. A. (2021) · Hepatology Communications · doi:10.1002/hep4.1773 · Cited by 2
Shalaby, S., Battistella, S., Zanetto, A., Bizzaro, D., Germani, G., Russo, F. P., & Burra, P. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.003 · Cited by 1
Non-alcoholic Fatty Liver Disease
Kim, S. F., & Choi, J. H. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_36-2 · Cited by 1
Lee, H., Kang, E. Y., Lee, J., Kim, Y., Kang, S., Kim, H., Kim, H. K., Gang, G., Lee, S. G., Cao, L., et al. (2023) · Food Science and Biotechnology · doi:10.1007/s10068-023-01464-1 · Cited by 1
Bandyopadhyay, S. K., Samajdar, S. S., Chaudhuri, S., & Das, S. (2024) · Hospital Practice · doi:10.1080/21548331.2024.2412513 · Cited by 3
DIABETIC FOOT ULCER PREVENTION THROUGH WORKPLACE WELLNESS PROGRAMS: CONCEPTUAL PERSPECTIVE
Bidin, A. A. M., Yen, N. S., & Noor, A. A. M. (2024) · Social Security Management Journal · doi:10.32890/ssmj2024.1.2.4 · Cited by 1
Tan, W., Deng, J., Qi, L., & Tan, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1467950 · Cited by 2
Demidova, T. Y., Расуловна, Б. А., & Омариевна, У. Ф. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-2-09 · Cited by 1
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502442 · Cited by 6
Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 2
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Efficacy and safety of insulin sensitisers for treating type 2 diabetes: a network meta-analysis
Huang, G., Li, Y., Shang, Y., Wang, H., Zhang, W., & Guo, H. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03882-y · Cited by 1
Kalapala, R., Jagtap, N., Rughwani, H., Asif, S., Sekaran, A., Sharma, M., Kulkarni, A., Rao, P. N., Tyagi, A., & Reddy, D. N. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103152 · Cited by 1
Taiwo, A., Thakkar, H., Maschek, J. A., Cox, J. E., Summers, S. A., Jalal, D. I., Dokun, A. O., Sivitz, W. I., & Chaurasia, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-15778-z · Cited by 2
Sabbagh, S., Hegazy, A., Adel, A., Ali, A., Alquddosy, M., Khalid, S., Ibrahim, A. M., Mohamed, A., Mostafa, A., Hassan, A., et al. (2025) · Cureus · doi:10.7759/cureus.92794 · Cited by 1
Liu, Y., Sun, Y., Zhou, T., Huang, X., Wang, G., & Sun, L. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107860 · Cited by 2
Luo, Z., Zhang, Y., Guo, C., Chen, L., Ma, Q., Wang, Y., Tang, Y., Zhang, J., & Chen, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149026 · Cited by 3
Park, S., Jo, M.-J., Ryu, Y., Seo, M.-G., Lee, J. W., Kim, Y. H., Kim, Y., & Park, S. (2025) · Nutrients · doi:10.3390/nu18010042 · Cited by 2
Deng, J., Liao, C., Liu, H., Tang, X., Yang, Y., Yang, Y., Guo, X., Zhang, S. H., Xing, K., Liao, M., et al. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s568066 · Cited by 1
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 3
Yang, K., Huang, Y., Gu, L., Li, J., Ma, Y., Gao, P., Qiu, W., Liu, K., Zhang, Y., Guan, L., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1768664 · Cited by 2
Knorr, J. P., Reese, R., Serbantez, M., & Lin, K. P. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag095 · Cited by 2
Guo, K., Cao, H., Wu, J., Wang, W. H., Lu, G., Wei, R., Huang, T., Wang, Y., Gao, Y., & Zhang, K. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121590 · Cited by 1
Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management
Lai, K. N., & Wong, V. W. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-167 · Cited by 2
Theodorou, R.-E., Vrettos, N., & Theodosis‐Nobelos, P. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48050465 · Cited by 2
Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
Praveen Sandeep Raj, R., John, R., Manoharan, F., Janeela, A. M., Goel, A., & Kapoor, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102107 · Cited by 6
Reframing MASLD: A Hepatic Condition With Systemic Clinical Impact
Castillo-Flores, P. S. N., Rodríguez‐Antonio, I., Uribe, M., Chávez-Tapia, N. C., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103631 · Cited by 2
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Diabetestherapie bei nichtalkoholischer Fettlebererkrankung
Bódis, K. B., & Roden, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0144-z · Cited by 1
Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root
Aggarwal, P., Singh, T., & Alkhouri, N. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00533-x · Cited by 1
Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Bagriy, A. E., Zubov, A. D., Khomenko, M. V., Михайличенко, Е. С., Пылаева, Е. А., Khaustova, N. A., & Bryukhovetskaya, E. V. (2021) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2021-31-2-14-26 · Cited by 3
Saavedra-Chacón, M. F., Pérez, S. T., & Guevara, L. G. (2021) · IATREIA · doi:10.17533/udea.iatreia.101 · Cited by 16
Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
Garbuzenko, D. V. (2022) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2021-31-5-16-24 · Cited by 1
The importance of glycemic control in non-alcoholic fatty liver disease
Ткач, С. М., Pankiv, V. І., Dorofeev, A. E., & Yuzvenko, V. (2022) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2022-2-20 · Cited by 1
Progress in the Treatment of Metabolism-Related Fatty Liver Disease
李, 红. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1291249 · Cited by 1
El Hígado graso (parte 2): enfoque clínico y tratamiento
Ortíz, J. E. P., Luque, C. B. S., & Quiróz, R. J. O. (2023) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.979 · Cited by 1
Obesity in the Pathophysiology of Diabetes
Paniagua, J. A., & Vidal‐Puig, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_14 · Cited by 1
Ansquer, J.-C. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_6 · Cited by 4
Praxisorientierte Strategien für Screening, Diagnostik und Therapie der NAFLD
Kreimeyer, H., Manka, P. P., & Canbay, A. E. (2023) · Gastro-News · doi:10.1007/s15036-023-3265-4 · Cited by 1
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis
Iwaki, M., Yoneda, M., Wada, N., Otani, T., Kobayashi, T., Nogami, A., Saito, S., & Nakajima, A. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2328036 · Cited by 1
Sinha, B., Ghosal, S., & Datta, D. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_10_24 · Cited by 1
Saroglitazar - A novel treatment for non-alcoholic steatohepatitis
Noorani, S., Ankam, M., Ganesh, C. H. S. V., Banu, R., Vani, P., Polarapu, N., Jangra, S., Shaima, K. A., & Bhyan, B. (2024) · AIP conference proceedings · doi:10.1063/5.0228900 · Cited by 1
Algoritmo de diagnóstico y tratamiento del sobrepeso y obesidad 2025 de la redGDPS
Fernández, L. C., Pérez, J. S., Fernández, C. G., & Vela, N. S. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.2.art3 · Cited by 1
Non-alcoholic Fatty Liver Disease in Non-obese Patients
Schmoyer, C. J., & Siddiqui, M. S. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0377-3 · Cited by 1
Pavlovskyi, S. A. (2018) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2018-1-2-143-170-175 · Cited by 1
Shypulin, V. P., Parunian, L. M., Tishchenko, V. V., Koliada, A. K., Ponomarov, O. M., & Melnyk, N. G. (2019) · Medical Science of Ukraine (MSU) · doi:10.32345/2664-4738.1-2.2019.04 · Cited by 1
Gautam, C., Sharma, J., Singla, M., Tiwana, I. K., & Singh, H. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.1.33 · Cited by 1
“Pioglitazone is also recommended for the treatment of patients with histology-proven NASH with or without diabetes mellitus, but its use is largely restricted because of its potential adverse effects.(15) A meta-analysis by Li et al.”
BackgroundFactors influencing circulating microRNAs as biomarkers for liver diseases
Dubey, S., Ashavaid, T. F., Abraham, P., & Paradkar, M. U. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07170-1 · Cited by 1
Die verfettete Leber in der Hausarztpraxis: Seminar / Nicht-alkoholische Fettlebererkrankung
Schulte‐Frohlinde, E. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-0618-1 · Cited by 1
Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie
Apostolopoulou, M., & Roden, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_20 · Cited by 1
Type 2 Diabetes Mellitus and Insulin Resistance in Nonalcoholic Fatty Liver Disease
Mihai, C., Mihai, B. M., & Prelipcean, C. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_14 · Cited by 1
Inzucchi, S. E., Viscoli, C. M., Young, L. H., Furie, K. L., Gorman, M., Lovejoy, A. M., Dagogo-Jack, S. E., Ismail‐Beigi, F., Korytkowski, M. T., Pratley, R. E., et al. (2017) · Diabetes Care · doi:10.2337/dci16-0048 · Cited by 1
“Because we did not measure liver fat directly, we do not know whether pioglitazone actually improved steatosis, but this is a reasonable inference based on previous trials (3).”
BackgroundYoung, L. H., Viscoli, C. M., Inzucchi, S. E., & Kernan, W. N. (2017) · Circulation · doi:10.1161/circulationaha.117.030513 · Cited by 1
Non‐alcoholic Fatty Liver Disease
Rotman, Y., & Kapuria, D. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch52 · Cited by 2
Azargoonjahromi, A. (2022) · Research Square · doi:10.21203/rs.3.rs-2179570/v1 · Cited by 1
Diabetes and Non‐alcoholic Fatty Liver Disease
Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch57 · Cited by 1
Khaliq, A., Badshah, H., Shah, Y., & Rehman, I. U. (2024) · Research Square · doi:10.21203/rs.3.rs-3982234/v1 · Cited by 1
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502639 · Cited by 1
A New Stereo Method Based On The Detector Of Local Structures
Cyganek, B., & Borgosz, J. (2002) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.37744
Diabetes medications improve cardiovascular outcomes: the paradigm shifts
Cusi, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000361
Self-citationLong-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis
Sutton, S. K. (2017) · Annals of Internal Medicine · doi:10.7326/l16-0627
Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
Cusi, K. J. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_4
Self-citationTargher, G., Mantovani, A., & Bonora, E. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_17-1 · Cited by 1
Nonalcoholic Fatty Liver Disease Treatment
Duvnjak, M., & Kralj, D. (2018) · Clinical gastroenterology · doi:10.1007/978-3-319-75856-5_23
Pavlovsky�, �. S. A. (2018) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2018-2-144-217-221
Metadata
- Authors
- Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., Webb, A., & Portillo-Sanchez, P.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- From University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida, and University of Texas Health Science Center at San Antonio and Audie L. Murphy Veterans Affairs Medical Center, San Antonio, Texas.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-09-06
- Volume
- 165
- Issue
- 5
- Pages
- 305-315
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2470709274
- Cited by
- 1,024
- References
- 62
- Citations by year
- 2026: 82 · 2025: 108 · 2024: 109 · 2023: 103 · 2022: 116 · 2021: 131 · 2020: 108 · 2019: 85 · 2018: 85 · 2017: 67 · 2016: 27
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- U.S. Department of Veterans Affairs (1 I01 CX000167-01)
- American Diabetes Association
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, nonalcoholic steatohepatitis, prediabetes, type 2 diabetes, long-term treatment, hypocaloric diet, NASH resolution, liver fibrosis, hepatic triglyceride content, insulin sensitivity, insulin resistance, PPARγ agonists, drug safety, adverse events, liver histopathology, hepatic steatosis
- MeSH terms
- Pioglitazone, Transaminases, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Prediabetic State, Triglycerides, Biomarkers, Weight Gain, Thiazolidinediones, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.